JP-ZLAB@EC2701A (14993.HK) Latest News & Headlines | Longbridge

© 2026 Longbridge｜Terms of Service Privacy Policy

ZAI LAB Interim Loss Widens to USD101.8M
AASTOCKS News·1 day ago, 08:21 PM
- ZAI LAB announced its interim results for the six months ended June 2026. - Total revenue decreased by 4.9% year-on-year to USD 205.9 million, while the net loss widened to USD 101.8 million. - The loss per share rose to US 9 cents, and no dividend was declared for the period.
ZLAB-0.53%09688+4.28%
Zai Lab’s Interim Results Show Lower Revenue but Rising R&D Investment
Tip Ranks·1 day ago, 05:40 PM
- Zai Lab reported unaudited interim results for the six months ended June 30, 2026, showing a 6% decline in net product revenue to $201.3 million due to weaker sales and pricing adjustments. - Research and development expenses rose 14% to $127.4 million, driving the net loss up 14% to $101.8 million and increasing the loss per share to $0.09. - The financial figures highlight the company's ongoing investments in its pipeline and partnerships despite facing short-term revenue and margin headwinds.
ZLAB-0.53%09688+4.28%
Inside Junshi's Global Push and COSCO's Energy Play
Global Report·1 day ago, 06:32 AM
01021-1.10%09688+4.28%
From Debt Restructurings to Biotech Breakthroughs: Hong Kong's Fractured Market in 2026
Global Report·1 day ago, 05:12 AM
061990.00%06106-1.30%
Weekly Recap | ZAI LAB +2.42%, positive Phase 3 data in myositis
Weekly Review·Aug 21 at 11:26 PM
09688+4.28%
Zai Lab CFO Chen Yajing sells 260 ADS worth $7,020
PUBT·Aug 21 at 03:17 PM
- Zai Lab CFO Chen Yajing sold 260 American Depositary Shares on Aug. 19, 2026, at USD 27 per share for a total of USD 7,020. - Following this transaction, executed under a Rule 10b5-1 plan adopted on Dec. 9, 2025, direct holdings totaled 35,635 ADS. - The transaction details were disclosed in a filing submitted to the U.S. Securities and Exchange Commission on August 21, 2026.
ZLAB-0.53%09688+4.28%
Zai Lab (ZLAB) Posts Positive Phase 3 Results In Autoimmune Myositis
Simplywall·Aug 19 at 06:42 AM
- Zai Lab and argenx announced positive Phase 3 ALKIVIA trial results for VYVGART Hytrulo in treating autoimmune myositis. - The successful trial represents a significant milestone for immune-mediated necrotizing myopathy, an underserved rare muscle disease with no previously approved therapies. - This development reinforces Zai Lab's immunology portfolio expansion while highlighting its reliance on externally sourced partnerships and licensed assets.
ARGX+2.71%ZLAB-0.53%
Top 10 HK Stock Gainers (8.19)
Top Gainers&Losers·Aug 19 at 03:30 AM
02506-2.73%02442+28.17%
Inside Hong Kong's Mixed Bag: Zai Lab's 2026 Push and WeRide Rumors
Global Report·Aug 18 at 04:44 AM
06960-2.27%02723+3.80%
Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock
Market Beat·Aug 13 at 04:22 PM
- Zai Lab CFO Yajing Chen sold 619 shares of stock at an average price of $25.00 on August 11th, reducing her position by 1.73% to 35,072 shares. - The transaction was disclosed in an SEC filing, following a previous sale of 2,264 shares on June 26th at an average price of $17.46. - Zai Lab holds a market cap of $2.96 billion and maintains a Moderate Buy consensus rating with an average target price of $40.20 among analysts.
ZLAB-0.53%09688+4.28%
Zai Lab CFO Chen Yajing sells 619 ADS worth $15,475
PUBT·Aug 13 at 03:16 PM
- Zai Lab CFO Chen Yajing sold 619 American Depositary Shares on Aug. 11, 2026, at a price of USD 25 per share. - The transaction total amounted to USD 15,475, reducing the CFO's holdings to 35,072 American Depositary Shares. - This regulatory filing information was published via the SEC EDGAR system on August 13, 2026.
ZLAB-0.53%09688+4.28%
Zai Lab audit committee to review and approve interim results publication
PUBT·Aug 13 at 04:03 AM
- Zai Lab's audit committee meeting is scheduled for Aug. 25, 2026, U.S. Eastern Time, or Aug. 26, 2026, Hong Kong Time. - The session will review and approve the company's unaudited condensed consolidated interim results for the six months ended June 30, 2026. - The original regulatory disclosure was published via the Hong Kong Stock Exchange IIS on August 13, 2026.
ZLAB-0.53%09688+4.28%
HK Midday: Hang Seng Range-Bound; Lenovo Soars Nearly 20% Post-Results; Tencent Slumps Over 4%
Market Pulse·Aug 13 at 01:22 AM
- Hong Kong stocks fluctuated in a narrow range during the session, with the Hang Seng Index reporting 25420 points and a turnover of about 1866 billion HKD. - Lenovo Group surged nearly 20% following record-breaking first-quarter results with revenue up 43% to 26.9 billion USD, driving AI and semiconductor sectors higher. - Tencent dropped over 4% as surging capital expenditures led to negative free cash flow, despite second-quarter revenue growing 11% to 204.8 billion RMB.
02513+9.42%09688+4.28%
MSCI China Index Adds Z.AI and KINGBOARD HLDG
AASTOCKS News·Aug 12 at 09:56 PM
- MSCI announced the results of its quarterly review, adding 33 stocks and removing 32 stocks from the MSCI China Index. - Key additions to the index include companies such as Z.AI and KINGBOARD HLDG, while notable removals feature GCL TECH and KINGDEE INT'L. - The index adjustments are scheduled to take effect after the market close on August 31.
ZLAB-0.53%HSAI-6.67%